Innate Pharma Analyst Ratings
Innate Pharma Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/18/2023 | 287.21% | HC Wainwright & Co. | → $11.5 | Reiterates | Buy → Buy |
06/16/2023 | 287.21% | HC Wainwright & Co. | → $11.5 | Reiterates | Buy → Buy |
03/24/2023 | 287.21% | HC Wainwright & Co. | → $11.5 | Reiterates | → Buy |
11/15/2022 | 203.03% | SVB Leerink | $10 → $9 | Maintains | Outperform |
09/16/2022 | 304.04% | Citigroup | $16 → $12 | Maintains | Buy |
08/02/2022 | 236.7% | SVB Leerink | $11 → $10 | Maintains | Outperform |
05/11/2022 | 270.37% | SVB Leerink | $10 → $11 | Maintains | Outperform |
09/17/2021 | 203.03% | SVB Leerink | $7 → $9 | Maintains | Outperform |
09/03/2021 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
09/02/2021 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
03/19/2021 | 135.69% | SVB Leerink | $5 → $7 | Maintains | Market Perform |
12/15/2020 | 68.35% | SVB Leerink | $7 → $5 | Downgrades | Outperform → Market Perform |
12/14/2020 | 287.21% | HC Wainwright & Co. | $13 → $11.5 | Maintains | Buy |
11/24/2020 | 59.93% | Goldman Sachs | → $4.75 | Initiates Coverage On | → Neutral |
09/09/2020 | 135.69% | SVB Leerink | $9 → $7 | Maintains | Outperform |
05/14/2020 | 203.03% | SVB Leerink | $10 → $9 | Maintains | Outperform |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
09/18/2023 | 287.21% | HC Wainwright & Co. | → 11.5 美元 | 重申 | 購買 → 購買 |
06/16/2023 | 287.21% | HC Wainwright & Co. | → 11.5 美元 | 重申 | 購買 → 購買 |
2023 年 3 月 24 日 | 287.21% | HC Wainwright & Co. | → 11.5 美元 | 重申 | → 購買 |
11/15/2022 | 203.03% | SVB Leerink | 10 美元 → 9 美元 | 維護 | 跑贏大盤 |
2022 年 9 月 16 日 | 304.04% | 花旗集團 | 16 美元 → 12 美元 | 維護 | 購買 |
08/02/2022 | 236.7% | SVB Leerink | 11 美元 → 10 美元 | 維護 | 跑贏大盤 |
05/11/2022 | 270.37% | SVB Leerink | 10 美元 → 11 美元 | 維護 | 跑贏大盤 |
09/17/2021 | 203.03% | SVB Leerink | 7 美元 → 9 美元 | 維護 | 跑贏大盤 |
2021 年 3 月 9 日 | — | SVB Leerink | 升級 | 市場表現 → 跑贏大盤 | |
2021 年 2 月 9 日 | — | SVB Leerink | 升級 | 市場表現 → 跑贏大盤 | |
03/19/2021 | 135.69% | SVB Leerink | 5 美元 → 7 美元 | 維護 | 市場表現 |
2020 年 12 月 15 日 | 68.35% | SVB Leerink | 7 美元 → 5 美元 | 降級 | 跑贏大盤 → 市場表現 |
2020 年 12 月 14 日 | 287.21% | HC Wainwright & Co. | 13 美元 → 11.5 美元 | 維護 | 購買 |
11/24/2020 | 59.93% | 高盛 | → 4.75 美元 | 啓動覆蓋範圍開啓 | → 中立 |
2020 年 9 月 9 日 | 135.69% | SVB Leerink | 9 美元 → 7 美元 | 維護 | 跑贏大盤 |
05/14/2020 | 203.03% | SVB Leerink | 10 美元 → 9 美元 | 維護 | 跑贏大盤 |
What is the target price for Innate Pharma (IPHA)?
Innate Pharma(IPHA)的目標價格是多少?
The latest price target for Innate Pharma (NASDAQ: IPHA) was reported by HC Wainwright & Co. on September 18, 2023. The analyst firm set a price target for $11.50 expecting IPHA to rise to within 12 months (a possible 287.21% upside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年9月18日公佈了Innate Pharma(納斯達克股票代碼:IPHA)的最新目標股價。該分析公司將目標股價定爲11.50美元,預計IPHA將在12個月內上漲至12個月內(可能上漲287.21%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Innate Pharma (IPHA)?
Innate Pharma(IPHA)的最新分析師評級是多少?
The latest analyst rating for Innate Pharma (NASDAQ: IPHA) was provided by HC Wainwright & Co., and Innate Pharma reiterated their buy rating.
Innate Pharma(納斯達克股票代碼:IPHA)的最新分析師評級由HC Wainwright & Co. 提供,Innate Pharma重申了買入評級。
When is the next analyst rating going to be posted or updated for Innate Pharma (IPHA)?
Innate Pharma(IPHA)的下一次分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Innate Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Innate Pharma was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.
分析師在進行了廣泛的研究後得出了股票評級,包括閱讀公開財務報表、與Innate Pharma的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應獲得4個評級。Innate Pharma的最後一次評級是在2023年9月18日提交的,因此你應該預計下一個評級將在2024年9月18日左右公佈。
Is the Analyst Rating Innate Pharma (IPHA) correct?
分析師對Innate Pharma(IPHA)的評級是否正確?
While ratings are subjective and will change, the latest Innate Pharma (IPHA) rating was a reiterated with a price target of $0.00 to $11.50. The current price Innate Pharma (IPHA) is trading at is $2.97, which is within the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但重申了Innate Pharma(IPHA)的最新評級,目標股價爲0.00美元至11.50美元。Innate Pharma(IPHA)目前的交易價格爲2.97美元,在分析師的預測區間內。
譯文內容由第三人軟體翻譯。